Loading clinical trials...

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

NCT01622348•Idera Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.

Detailed Description

To evaluate the safety, tolerability and treatment effect of different dose levels of IMO-3100 compared to placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Is age 18 to 70 years, inclusive;
•Completes the informed consent procedure (see Section 15.3), including signing and dating the informed consent form;
•Has moderate to severe plaque psoriasis meeting the criteria specified above;
•Female subjects must have a negative pregnancy test at screening and on Day 1 prior to start of treatment;
•Female subjects of childbearing potential (see Section 8.4.1) and male subjects who have partners of childbearing potential must agree to use effective birth control (contraception; see Section 8.4.1) from Screening through the treatment period and for four (4) weeks after the last injection of study drug.

Exclusion Criteria

•Has known hypersensitivity to any oligodeoxynucleotide;
•Is nursing;
•Has body weight \< 50 kg;
•Has BMI \> 34.9 kg/m2;
•Regularly consumes \> 3 drinks of alcoholic beverages (beer, wine, or distilled spirits) per day;
•Has a positive test for antibody to human immunodeficiency virus (HIV-1 or -2) or hepatitis C virus;
•Has a positive test for hepatitis B surface antigen (HBsAg);
•Has at screening safety laboratory tests meeting one or more of the following criteria:
•hemoglobin \< 10.5 g/dL
•white blood cell count \< 4,000 cells/mm3
+14 more criteria

Locations (13)

Florida Center for Dermatology, P.A

Jacksonville, Florida, United States

Atlanta Dermatology, Vein & Research Center, PC

Alpharetta, Georgia, United States

Dermatologic Surgery Specialists, Inc.

Macon, Georgia, United States

Indiana Clinical Trials Center, PC

Plainfield, Indiana, United States

DermResearch PLLC

Louisville, Kentucky, United States

Tufts Medical Center

Boston, Massachusetts, United States

Mass General Hospital Clinical Unit for Research Trials in Skin

Boston, Massachusetts, United States

Derm Research Center of New York

Stony Brook, New York, United States

Oregon Dermatology and Research Center

Portland, Oregon, United States

Clinical Partners, Inc

Johnston, Rhode Island, United States

Key Dates

Start Date

May 1, 2012

Primary Completion Date

November 1, 2012

Completion Date

December 1, 2012

Last Updated

January 9, 2018

Enrollment

ACTUAL participants

Conditions

Actively Extending Plaque PsoriasisModerate to Severe Plaque Psoriasis

Interventions

IMO-3100 at 0.16 mg/kg

DRUG

Saline for Injection

DRUG

IMO-3100 at 0.32 mg/kg

DRUG

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193

Moderate to Severe Plaque PsoriasisPsoriatic Arthritis+2 more

View study

RECRUITINGNA

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

NCT07234591

Plaque PsoriasisModerate to Severe Plaque Psoriasis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis